On Thursday 05/22/2025 the closing price of the Precigen share was $1.40 on BTT.
Compared to the opening price on Thursday 05/22/2025 on BTT of $1.37, this is a gain of 1.79%.
Precigen's market capitalization is $332.77 M by 295.18 M shares outstanding.
Is Precigen stock a Buy, Sell or Hold?
Precigen stock has received a consensus rating of buy. The average rating score is and is based on 11 buy ratings, 0 hold ratings, and 0 sell ratings.What was the 52-week low for Precigen stock?
The low in the last 52 weeks of Precigen stock was 0.65. According to the current price, Precigen is 207.95% away from the 52-week low.What was the 52-week high for Precigen stock?
The high in the last 52 weeks of Precigen stock was 2.17. According to the current price, Precigen is 62.82% away from the 52-week high.What are analysts forecasts for Precigen stock?
The 11 analysts offering price forecasts for Precigen have a median target of 8.64, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a 15.75 difference from the last price of 1.36.Precigen Stock Snapshot
1.35
Bid
300.00
Bid Size
1.37
Ask
300.00
Ask Size
5/23/2025
Date
3:59 PM
Time
93,114.00
Volume
1.40
Prev. Close
1.37
Open
404.89 M
Market Cap in USD
295.18 M
Number of Shares
295.18 M
Total Number of Shares
1.36
Day Low
1.43
Day High
1.36
0.65
52 Week Low
2.17
52 Week High
1.36
0.00
Dividend in USD
0.00
Dividend Yield
54.86
Free Float in %
-0.47
EPS in USD
0.13
Book Value per Share in USD
-0.25
Cash Flow per Share in USD
Precigen News More News
Historical Prices for Precigen
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Precigen Analyst Data
Total Analysts: 11
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 6.00
Median: 8.64
Highest: 14.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Precigen Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/15/25 | Cantor Fitzgerald | Maintained Buy | ||||
| 03/20/25 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 01/23/25 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 06/04/24 | JMP Securities LLC | Maintained Buy | $14 | |||
| 06/03/24 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $10 | |||
| 06/03/24 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 05/15/24 | Cantor Fitzgerald | Maintained Buy | ||||
| 05/15/24 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $7 | |||
| 05/15/24 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 03/22/24 | J.P. Morgan | Downgraded to Sell | ||||
| 03/20/24 | JMP Securities LLC | Maintained Buy | $14 | |||
| 03/20/24 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 08/10/23 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 06/05/23 | JMP Securities LLC | Maintained Buy | $14 |
Precigen Estimates* in USD
| 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|
| Revenue | 14 | 118 | 272 | 377 | 481 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -0.35 | -0.04 | 0.29 | 0.49 | 0.71 |
| P/E Ratio | -3.89 | -34.25 | 4.81 | 2.80 | 1.94 |
| EBIT | -85 | 19 | 106 | 180 | 258 |
| EBITDA | -101 | - | - | - | - |
| Net Profit | -108 | -10 | 90 | 157 | 228 |
| Net Profit Adjusted | -101 | 33 | 121 | 185 | 240 |
| Pre-Tax Profit | -104 | 19 | 106 | 180 | 258 |
| Pre-Tax Profit Reported | -94 | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | -0.35 | -0.04 | 0.29 | 0.49 | 0.71 |
| EPS (GAAP) | -0.32 | 0.11 | - | - | 0.79 |
| Gross Income | 13 | 120 | 224 | 312 | 401 |
| Cash Flow from Investing | -36 | - | - | - | - |
| Cash Flow from Operations | -90 | - | - | - | - |
| Cash Flow from Financing | 141 | - | - | - | - |
| Cash Flow per Share | -0.26 | - | - | - | - |
| Free Cash Flow | -101 | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | - | - | - | - | - |
| Research & Development Exp. | 39 | 37 | 39 | 42 | 45 |
| Capital Expenditure | 11 | - | - | - | - |
| Selling, General & Admin. Exp. | 52 | 66 | 79 | 90 | 98 |
| Shareholder’s Equity | 170 | - | - | - | - |
| Total Assets | 190 | - | - | - | - |
|
Previous Quarter ending 03/31/25 |
Current Quarter ending 06/30/25 |
Next Quarter ending 09/30/25 |
Current Year ending 12/31/25 |
Next Year ending 12/31/26 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 3 | 3 | 4 | 3 |
| Average Estimate | - | -0.083 USD | -0.077 USD | -0.353 USD | -0.040 USD |
| Year Ago | - | -0.233 USD | -0.087 USD | -0.472 USD | - |
| Publish Date | - | 8/11/2025 | 11/12/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 3 | 3 | 4 | 3 |
| Average Estimate | - | 1 USD | 1 USD | 14 USD | 118 USD |
| Year Ago | - | 1 USD | 1 USD | 4 USD | - |
| Publish Date | - | 8/11/2025 | 11/12/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales | 3.93 | 6.23 | 26.91 | 103.87 | 103.18 | 90.72 | 160.57 |
| Change of sales in % | -36.95 | -76.87 | -74.09 | 0.67 | 13.73 | -43.50 | -30.48 |
| Gross profit on sales | -3.40 | -4.74 | 15.77 | 45.49 | 47.67 | 29.32 | 97.29 |
| Gross profit on sales change in % | 28.28 | - | -65.33 | -4.57 | 62.56 | -69.86 | -42.16 |
| Operating income | -94.71 | -88.92 | -74.61 | -78.78 | -85.68 | -173.40 | -208.41 |
| Operating income change in % | -6.50 | -19.19 | 5.29 | 8.06 | 50.59 | 16.80 | -75.83 |
| Income before tax | -128.03 | -96.36 | -79.97 | -96.93 | -103.86 | -208.69 | -536.23 |
| Income before tax change in % | -32.86 | -20.50 | 17.50 | 6.67 | 50.23 | 61.08 | -313.44 |
| Income after tax | -126.24 | -95.90 | -79.78 | -96.77 | -103.77 | -206.17 | -509.34 |
| Income after tax change in % | -31.63 | -20.22 | 17.56 | 6.75 | 49.67 | 59.52 | -335.26 |
Balance Sheet in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 79.81 | 41.64 | 98.89 | 257.65 | 257.13 | 399.30 | 342.91 |
| Long-term liabilities per share | 0.20 | 0.07 | 0.10 | 1.08 | 1.15 | 1.69 | 1.76 |
| Equity | 66.73 | 118.50 | 126.26 | 107.35 | 67.17 | 71.71 | 378.72 |
| Equity change in % | -67.50 | -6.15 | 17.62 | 59.81 | -6.33 | -80.24 | -32.00 |
| Balance sheet total | 146.54 | 160.14 | 225.15 | 365.00 | 324.31 | 471.01 | 721.63 |
| Balance sheet total change in % | -8.50 | -28.87 | -38.32 | 12.55 | -31.15 | -34.73 | -14.79 |
Key Data in USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 0.01 | 0.03 | 0.13 | 0.53 | 0.62 | 0.59 | 1.24 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 45.54 | 74.00 | 56.08 | 29.41 | 20.71 | 15.23 | 52.48 |
| Debt ratio in % | 54.46 | 26.00 | 43.92 | 70.59 | 79.29 | 84.77 | 47.52 |
Precigen Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Sabzevari Helen | 05/15/2025 | 521,224.00 | 3,317,022.00 | 1.45 | Sell | No |
| Tennant Phil | 05/15/2025 | 22,969.00 | 59,031.00 | 1.45 | Sell | No |
| Lehr Donald P. | 05/15/2025 | 55,101.00 | 681,649.00 | 1.45 | Sell | No |
| Thomasian Harry Jr. | 05/15/2025 | 51,441.00 | 457,410.00 | 1.45 | Sell | No |
| Sabzevari Helen | 05/15/2025 | 1,079,137.00 | 3,838,246.00 | n/a | Buy | No |
| Tennant Phil | 05/15/2025 | 66,441.00 | 82,000.00 | n/a | Buy | No |
| Lehr Donald P. | 05/15/2025 | 165,468.00 | 736,750.00 | n/a | Buy | No |
| Thomasian Harry Jr. | 05/15/2025 | 154,475.00 | 508,851.00 | n/a | Buy | No |
| KINDLER JEFFREY B | 03/13/2025 | 87,412.00 | 520,430.00 | n/a | Buy | No |
| Frank Steven | 03/13/2025 | 87,412.00 | 1,140,307.00 | n/a | Buy | No |
| ALVAREZ CESAR L | 03/13/2025 | 87,412.00 | 693,264.00 | n/a | Buy | No |
| Hassan Fred | 03/13/2025 | 87,412.00 | 1,153,452.00 | n/a | Buy | No |
| Turley James S | 03/13/2025 | 87,412.00 | 595,772.00 | n/a | Buy | No |
| KIRK RANDAL J | 03/13/2025 | 174,825.00 | 64,779,510.00 | n/a | Buy | No |
| Gupta Vinita D | 03/13/2025 | 87,412.00 | 576,240.00 | n/a | Buy | No |
| KINDLER JEFFREY B | 03/12/2025 | 39,655.00 | 433,018.00 | 1.74 | Buy | No |
| AGEE NANCY H | 03/12/2025 | 32,471.00 | 50,076.00 | 1.74 | Buy | No |
| Frank Steven | 03/12/2025 | 28,735.00 | 1,052,895.00 | 1.74 | Buy | No |
| ALVAREZ CESAR L | 03/12/2025 | 35,919.00 | 605,852.00 | 1.74 | Buy | No |
| Hassan Fred | 03/12/2025 | 36,206.00 | 1,066,040.00 | 1.74 | Buy | No |
| Turley James S | 03/12/2025 | 35,919.00 | 508,360.00 | 1.74 | Buy | No |
| KIRK RANDAL J | 03/12/2025 | 57,471.00 | 64,604,685.00 | 1.74 | Buy | No |
| Gupta Vinita D | 03/12/2025 | 36,206.00 | 488,828.00 | 1.74 | Buy | No |
| Tennant Phil | 01/28/2025 | 9,441.00 | 15,559.00 | 1.30 | Sell | No |
| Lehr Donald P. | 01/28/2025 | 20,844.00 | 571,282.00 | 1.30 | Sell | No |
Precigen Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2024 | Precigen | 0.00 | 0.00 | USD |
| 2023 | Precigen | 0.00 | 0.00 | USD |
| 2022 | Precigen | 0.00 | 0.00 | USD |
| 2021 | Precigen | 0.00 | 0.00 | USD |
| 2020 | Precigen | 0.00 | 0.00 | USD |
| 2019 | Precigen | 0.00 | 0.00 | USD |
| 2018 | Precigen | 0.00 | 0.00 | USD |
| 2017 | Precigen | 0.00 | 0.00 | USD |
| 2016 | Precigen | 0.00 | 0.00 | USD |
| 2015 | Precigen | 0.00 | 0.00 | USD |
| 2014 | Precigen | 0.00 | 0.00 | USD |
| 2013 | Precigen | 0.00 | 0.00 | USD |
| 2012 | Precigen | 0.00 | - | USD |
| 2011 | Precigen | - | - | USD |
*Yield of the Respective Date
Precigen Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Annual General Meeting | -0.470 USD | Annual General Meeting | 06/26/2025 |
| Earnings Report | -0.083 USD | Q2 2025 Earnings Release | 08/11/2025 |
| Earnings Report | -0.077 USD | Q3 2025 Earnings Release | 11/12/2025 |
| Earnings Report | -0.043 USD | Q4 2025 Earnings Release | 03/09/2026 |
| Earnings Report | -0.020 USD | Q1 2026 Earnings Release | 05/13/2026 |
Precigen Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | -0.180 USD | Q1 2025 Earnings Release | 05/14/2025 |
| Earnings Report | -0.060 USD | Q4 2024 Earnings Release | 03/19/2025 |
| Earnings Report | -0.090 USD | Q3 2024 Earnings Release | 11/14/2024 |
| Earnings Report | -0.230 USD | Q2 2024 Earnings Release | 08/14/2024 |
| Annual General Meeting | -0.390 USD | Annual General Meeting | 07/05/2024 |
| Earnings Report | -0.100 USD | Q1 2024 Earnings Release | 05/14/2024 |
| Earnings Report | -0.130 USD | Q4 2023 Earnings Release | 03/19/2024 |
| Earnings Report | -0.080 USD | Q3 2023 Earnings Release | 11/09/2023 |
| Earnings Report | -0.080 USD | Q2 2023 Earnings Release | 08/09/2023 |
| Annual General Meeting | 0.140 USD | Annual General Meeting | 06/08/2023 |
| Earnings Report | -0.100 USD | Q1 2023 Earnings Release | 05/10/2023 |
| Earnings Report | -0.110 USD | Q4 2022 Earnings Release | 03/06/2023 |
| Earnings Report | 0.440 USD | Q3 2022 Earnings Release | 11/09/2022 |
| Earnings Report | -0.090 USD | Q2 2022 Earnings Release | 08/08/2022 |
| Annual General Meeting | -0.470 USD | Annual General Meeting | 06/09/2022 |
| Earnings Report | -0.100 USD | Q1 2022 Earnings Release | 05/09/2022 |
| Earnings Report | -0.130 USD | Q4 2021 Earnings Release | 03/01/2022 |
Precigen Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.